Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 3
1985 7
1986 2
1987 2
1988 4
1989 1
1990 1
1991 2
1992 1
1993 3
1994 3
1997 1
1998 6
1999 6
2000 6
2001 10
2002 11
2003 6
2004 10
2005 12
2006 7
2007 8
2008 3
2009 4
2010 8
2011 7
2012 4
2013 7
2014 7
2016 10
2017 23
2018 11
2019 3
2020 3
2021 2
2022 6
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Syringomatous carcinoma and its dermoscopic features.
Nojima K, Namiki T, Hanafusa T, Miura K, Yokozeki H. Nojima K, et al. Australas J Dermatol. 2017 Aug;58(3):e152-e153. doi: 10.1111/ajd.12528. Epub 2017 Jun 30. Australas J Dermatol. 2017. PMID: 28664571 No abstract available.
Parallel ridge pattern above an arteriovenous malformation.
Namiki T, Chikazawa S, Nojima K, Ueno M, Miura K, Tanaka M, Yokozeki H. Namiki T, et al. Among authors: nojima k. J Dermatol. 2017 Jul;44(7):e160-e161. doi: 10.1111/1346-8138.13812. Epub 2017 Mar 7. J Dermatol. 2017. PMID: 28266053 No abstract available.
Kikuchi's disease: cutaneous involvement and dermoscopic features.
Sone Y, Namiki T, Nojima K, Hashimoto T, Hanafusa T, Tokoro S, Miura K, Yokozeki H. Sone Y, et al. Among authors: nojima k. Eur J Dermatol. 2017 Apr 1;27(2):212-213. doi: 10.1684/ejd.2016.2958. Eur J Dermatol. 2017. PMID: 28098071 No abstract available.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: nojima k. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: nojima k. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I. Seki Y, et al. Among authors: nojima k. Med. 2022 Jun 10;3(6):406-421.e4. doi: 10.1016/j.medj.2022.04.013. Epub 2022 Apr 26. Med. 2022. PMID: 35815933 Free PMC article.
199 results